BackCorMedix Overview
CorMedix Inc

CorMedix Target Price

Analysts' average 12-month price target for CorMedix is $15.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.66

Average Target Price

$15.25227.3% upside

4 analysts in the last 4 months

High: $19 | Low: $13

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-13OppenheimerLes Sulewski$13179% upsideOpen
2026-11-10NeedhamSerge Belanger$14200.4% upsideOpen
2026-11-10UBS$19307.7% upsideOpen
2026-09-23OppenheimerLes Sulewski$15221.9% upsideOpen
2026-04-28RBC CapitalLeonid Timashev$14200.4% upsideOpen
2026-03-06Leerink PartnersRoanna Ruiz$13179% upsideOpen
2026-01-23H.C. Wainwright$13179% upsideOpen
2026-01-21RBC Capital$13179% upsideOpen
2026-01-08Truist Financial$16243.3% upsideOpen
2025-10-21RBC CapitalGregory Renza$22372.1% upsideOpen
2025-08-08H.C. WainwrightBrandon Folkes$17264.8% upsideOpen
2024-03-13RBC CapitalGregory Renza$993.1% upsideOpen

CorMedix (CRMD) FAQ

CorMedix's target price stands at $15. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $15 for CRMD implies 227.3% upside versus today's price ($4.66). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how CorMedix's target price evolved across reporting periods, while the comparison chart places CRMD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. CorMedix's reading of $15 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.